Document is current
Any future updates will be listed below
-
Authors
Thatikonda, Venu http://orcid.org/0009-0005-3886-8475
Lyu, Hengyu http://orcid.org/0000-0003-1093-9364
Jurado, Sabine
Kostyrko, Kaja http://orcid.org/0000-0002-2842-4089
Bristow, Christopher A.
Albrecht, Christoph
Alpar, Donat http://orcid.org/0000-0002-2638-5418
Arnhof, Heribert
Bergner, Oliver
Bosch, Karin
Feng, Ningping
Gao, Sisi
Gerlach, Daniel http://orcid.org/0000-0001-9338-3765
Gmachl, Michael
Hinkel, Melanie http://orcid.org/0000-0002-0966-8045
Lieb, Simone
Jeschko, Astrid
Machado, Annette A.
Madensky, Thomas
Marszalek, Ethan D.
Mahendra, Mikhila
Melo-Zainzinger, Gabriella
Molkentine, Jessica M. http://orcid.org/0000-0002-3757-7167
Jaeger, Philipp A.
Peng, David H.
Schenk, Robyn L.
Sorokin, Alexey
Strauss, Sandra
Trapani, Francesca
Kopetz, Scott http://orcid.org/0000-0001-9647-3416
Vellano, Christopher P.
Petronczki, Mark
Kraut, Norbert http://orcid.org/0000-0003-3941-7105
Heffernan, Timothy P. http://orcid.org/0000-0002-3166-8922
Marszalek, Joseph R. http://orcid.org/0000-0003-2320-3209
Pearson, Mark
Waizenegger, Irene C.
Hofmann, Marco H. http://orcid.org/0000-0001-7557-1156
- License Information
-
More Information
Article History
Received: 23 January 2023
Accepted: 8 July 2024
First Online: 5 August 2024
Competing interests
: V.T., S.J., K.K., D.A., H.A., O.B., K.B., D.G., M.G., M.H., S.L., A.J., C.A., T.M., G.M.-Z., P.A.J., R.L.S., S.S., F.T., M. Petronczki, N.K., M. Pearson, I.W. and M.H.H. report grants from the Austrian Research Promotion Agency (FFG) and have received personal fees from Boehringer Ingelheim (full-time employee) during the conduct of the study. V.T. is now a full-time employee for Exscientia, Vienna, Austria. M.H.H. and M.G. have been listed as the inventors on patent applications for SOS1 inhibitors. A.S., S.K., H.L., A.A.M., M.M., E.D.M., S.G., N.F., C.A.B., D.H.P., J.M.M., C.P.V., T.P.H. and J.R.M. report other from Boehringer Ingelheim (sponsored research) during the conduct of the study and this work was performed under a sponsored research collaboration between MD Anderson and Boehringer Ingelheim, for which the latter provided funding support. S. K. has ownership interest in Lutris, Iylon, Frontier Medicines, Xilis and Navire and is a consultant for Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, AstraZeneca/MedImmune, Bayer Health, Redx Pharma, Ipsen, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, Abbvie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho Pharmaceutical, Cardiff Oncology, Ono Pharmaceutical, Bristol-Myers Squibb-Medarex, Amgen, Tempus, Foundation Medicine, Harbinger Oncology, Takeda, CureTeq, Zentalis, Black Stone Therapeutics, NeoGenomics Laboratories and Accademia Nazionale Di Medicina, and receive research funding from Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly and Daiichi Sankyo. T.P.H. receives advisory fees from Cullgen and Roivant Discovery.
